Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/31/13
End: 12/31/16
Due: 12/31/17
Phase: N/A
Priority: Normal
Start: 01/31/16
End: 06/30/17
Due: 06/30/18
Phase: N/A
Priority: Normal
Start: 04/30/09
End: 10/31/11
Due: 10/31/12
Phase: N/A
Priority: Normal
Start: 11/30/07
End: 02/28/14
Due: 02/28/15
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion | NCT01827722 | Valley Retina Institute | user2@example.com | None | 2013-05-31 | 2016-12-31 | 2017-12-31 | - | - | 2025-07-14 |
| Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept injectioN | NCT02630277 | Valley Retina Institute | user2@example.com | None | 2016-01-31 | 2017-06-30 | 2018-06-30 | - | - | 2025-07-14 |
| Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study | NCT01486238 | Valley Retina Institute | user2@example.com | None | 2009-04-30 | 2011-10-31 | 2012-10-31 | - | - | 2025-07-14 |
| Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED) | NCT01486771 | Valley Retina Institute | user2@example.com | None | 2007-11-30 | 2014-02-28 | 2015-02-28 | - | - | 2025-07-14 |